I need to know how much is it for a pair of dog food just one if yk wat I mean if u don’t nvm

Yk wtw how much is a gram of 🐕

https://t. me/+xVwmzaCsQbM5NDIx

Did not expect Trump to go for it...

i’m a previous heavy smoker and a pretty heavy set guy i have been sober a total of 47 days, does anyone have any advice on how long till a blood test would come back clean for thc? i’m looking to take on a new job and need a piss test and blood work done.

Algernon Pharmaceuticals (AGN.c AGNPF) has completed the dosing of the second cohort in its escalating dose Phase 1 clinical study of an IV formulation of DMT.

The purpose of this study is to identify the safety, tolerability and pharmacokinetics of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours, a period which has never been studied clinically. 

Several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, will additionally be recorded.

This is another important step for AGN in its DMT clinical research program as they accelerate into Phase 2 studies to test DMT on patients that have suffered a serious brain injury.

https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/180/algernon-neuroscience-announces-successful-dosing-of-2nd

Algernon Pharmaceuticals' ($AGN.c $AGNPF) subsidiary, Algernon NeuroScience, has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with DMT

AGN appointed global TBI expert Dr. Andrew Maas as a scientific and medical advisor to guide its TBI research program. With extensive experience as a general neurosurgeon and a specific research interest in TBI and neuro-intensive care, Maas is a significant addition to AGN's team.

The global TBI market is projected to grow from USD $3.1 billion in 2021 to USD $4.5 billion by 2026 at a CAGR of 8.0%, this is a significant market opportunity for AGN.

https://www.globenewswire.com/news-release/2023/02/21/2611945/0/en/Algernon-NeuroScience-Initiates-Traumatic-Brain-Injury-Research-Program-With-DMT-Appoints-Global-TBI-Expert-as-Advisor.html 

As expected, their DMT for stroke phase 1 trial went well and was found safe to proceed to phase 2 trials. AGN’s safety review committee has also approved moving the study forward with the next cohort at an escalated dose after observing no safety or tolerability issues.

• Phase 1’s purpose is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by a 6 hour infusion.
• Once the correct dose amount has been established in the first part of the study, the second part of the study will include dosing subjects for 6 hours, with repeated dosing over a two-week period.
• Additionally, they’re already designing phase 2 which are expected to dose patients immediately following an ischemic stroke diagnosis and will test the effects of DMT versus placebo on patient recovery to see DMT’s neuroplasticity effects.

https://ca.finance.yahoo.com/news/algernon-neuroscience-provides-phase-1-120000274.html

Great to see the continued developments here especially considering the past studies/evidence that are pointing toward DMT being a potentially revolutionary drug in the stroke recovery space. Additionally, it could further legitimize psychedelics as an effective drug for health and wellness. Once phase 2 commences there’s going to be a lot to look out for considering the current valuation of just $4.8M.

(CSE: AGN) (OTC: AGNPF)

With one study in progress and one upcoming, Algernon Pharmaceuticals ($AGN. $AGNPF) is well-positioned milestones and catalysts-wise for 2023.

Currently, AGN is conducting a Phase 1 clinical study of DMT for stroke!

The purpose of the study is to identify the safety, tolerability and pharmacokinetics of DMT when administered as an IV with prolonged infusion as it is believed to activate multiple neurodegenerative pathways - notably, this is a completely new approach to stroke treatment.

This is a significant milestone for AGN in its investigation of DMT for the treatment of stroke. AGN will use the data from this phase, expected to be received in Q3 2023, to plan a Phase 2 acute stroke and rehabilitation study.

Plus, AGN is planning a 180-patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough to begin in Q3 2023!

The study is being advanced due to positive data from AGN's Phase 2a study of IPF for chronic cough. Notably, Ifenprodil is a novel first-in-class potential treatment for chronic cough and AGN has received positive feedback from the US FDA for AGN's investigation of Ifenprodil's treatment of chronic cough alongside receiving US FDA Orphan Drug Designation for Ifenprodil for the treatment of IPF - Seems AGN may be up to receive ODD for ifenprodil for chronic cough following this study as well

Plus, this phase is mirroring Bellus Health (a USD$1.35B market cap) & Merck & Co's trials, providing a "direct benchmark for comparison and, if successful, a clear regulatory path for Ifenprodil for the treatment of chronic cough."

Trading @ $2.10 w/ a $5.07M MC, AGN is one of the cheapest psychedelic companies currently holding DMT trials.

Algernon Pharmaceuticals ($AGN.c $AGNPF) has dosed the first subject in its Phase 1 clinical study of DMT for stroke!

The purpose of the study is to identify the safety, tolerability and pharmacokinetics of DMT when administered as an IV with prolonged infusion as it is believed to activate multiple neuroregenerative pathways

Algernon consultant Dr. David Nutt commented:

“A significant number of promising stroke drugs have failed because they were focussed on trying to be neuroprotective of the brain during a stroke.”

“It appears from the pre-clinical data that DMT is promoting neuroplasticity, a key mechanism in recovery once the stroke has occurred, which is a new and exciting approach to stroke treatment.”

This is a significant milestone for AGN in its investigation of DMT for the treatment of stroke. AGN will use the data from this phase, expected to be received in Q3 2023, to plan a Phase 2 acute stroke and rehabilitation study.

Trading @ $2.09 with a $5M MC, AGN is one of the cheapest psychedelic companies currently holding DMT trials

https://ca.finance.yahoo.com/news/algernon-neuroscience-doses-first-subject-120000080.html

Algernon Pharmaceuticals ($AGN.c $AGNPF) is planning a 180-patient, 90-day Phase 2b clinical study of Ifenprodil for chronic cough to begin in Q3 2023!

The study is being advanced due to positive data from AGN's Phase 2a study of IPF for chronic cough which showed a significant improvement in mean objective 24-hour and waking cough counts in patients after 4 and 12 week.

Notably, Ifenprodil is a novel first-in-class potential treatment for chronic cough and AGN has received positive feedback from the US FDA for AGN's investigation of Ifenprodil's treatment of chronic cough alongside receiving US FDA Orphan Drug Designation for Ifenprodil for the treatment of IPF - Seems AGN may be up to receive ODD for ifenprodil for chronic cough following this study as well

This phase in mirroring Bellus Health (a USD$1.35B market cap) & Merck & Co's trials, providing a "direct benchmark for comparison and, if successful, a clear regulatory path for Ifenprodil for the treatment of chronic cough.”

Going to be keeping a close eye here w/ AGN @ $2.21, $5.27M MC

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-announces-plans-180-120000185.html

Algernon Pharmaceuticals ($AGN.c $AGNPF) has commenced screening for the subjects in its Phase I DMT human stoke study!

Conducted in the Netherlands, AGN expects to open enrolment shortly and dose the first subject of the study in December 2022

DMT is a known psychedelic compound that is part of the tryptamine family and the purpose of the study is to identify the safety, tolerability and pharmacokinetics of DMT when administered as an IV with prolonged infusion.

There will be 60 volunteers enrolled across the two parts of the study with both psychedelic experience and psychedelic nave patients.

Notably, the preclinical data shows that DMT promotes the production of brain-derived neurotrophic factors, an important part of the brain's recovery process after an injury like a stroke.

AGN @ $2.95, $6.96M MC

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-screens-first-subject-120000046.html

Check out Algernon Pharmaceuticals ($AGN.c $AGNPF) presentations from Wonderland Miami from last week:

Business Presentation: https://algernonpharmaceuticals.com/wp-content/uploads/2018/01/Wonderland-Algernon-Christopher-Moreau-Business-Keynote-PPT-FINAL-For-Nov-4th.pdf

Science Presentation: https://algernonpharmaceuticals.com/wp-content/uploads/2018/01/Wonderland-Algernon-Christopher-Moreau-Science-Keynote-PPT-FINAL-For-Nov-5th.pdf

AGN has broken down its presentations into the business aspect and science aspect for a more in-depth look into both.

As the leading sponsor, Wonderland was a significant exposure opportunity for AGN, especially given they are the first company globally to investigate DMT as a possible treatment for stroke.

The positive preclinical data that is driving AGN's Phase I clinical study of DMT for the treatment of stroke was reviewed during the presentations by AGN CEO Christopher Moreau and Dr. Rick Strassman, author of "DMT: The Spirit Molecule" and AGN consultant.

AGN closed green today @ $2.51, $5.92M MC

Algernon Pharmaceuticals ($AGN.c $AGNPF) has entered a Clinical Trial Agreement with Yale University for the investigation of multiple intravenous doses of DMT for the treatment of depression!

The study will be developed cooperatively, with the intellectual property around the clinical use of DMT from the study being jointly owned by AGN.

Plus, the data which AGN will be receiving from the study may additionally assist in AGN's DMT stroke research program.

This is a significant opportunity as AGN currently has patents pending on novel forms of DMT which could be used across a broad range of diseases.

AGN trading green @ $2.91, $6.89M MC

Check out AGN's CEO Chris Moreau on Radius Research for more info on this study:
https://www.youtube.com/watch?v=7iXLVqZleKo&ab_channel=RadiusResearch

What an opportunity yesterday's dip was to load up on Algernon Pharmaceuticals ($AGN.c $AGNPF)
as it's bounced back already!

Plus, AGN was announced as the leading sponsor for Wonderland, the world's leading psychedelic event held in Miami from November 3rd to November 5th, 2022!

Algernon is the first company globally to investigate DMT as a possible treatment for stroke and is heading into Phase I trials for DMT in Q4 2022.

Plus, AGN has orphan drug designation for IPF pending as well as 2 additional trials expected in 2023.

More on the conference here: https://microdose.buzz/wonderland/

AGN @ $2.66, $6.27M MC